<DOC>
	<DOCNO>NCT00344305</DOCNO>
	<brief_summary>Open label , single arm , multicenter study shed safety single dose trivalent , influenza virus vaccine live , intranasal child 6 &lt; 60 month age , 28-day shed follow-up 180-day safety follow-up .</brief_summary>
	<brief_title>A Study Evaluate Shedding Safety Trivalent Influenza Virus Vaccine Live , Intranasal Infants Young Children</brief_title>
	<detailed_description>This Phase 2 , open-label , single-arm , multicenter study design evaluate vaccine virus shed safety trivalent influenza virus vaccine live , intranasal child 6 &lt; 60 month age . Enrollment approximately 200 subject stratify age , 100 subject 6 &lt; 24 month age ( reach sixth month second year birthday ) 100 subject 24 &lt; 60 month age ( reach second year fifth year birthday ) . Baseline medical history data collection include subject 's prior receipt influenza vaccine history laboratory-confirmed influenza illness previous influenza season .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female , 6 month le 60 month age ( reach 6th month yet reach 5th year birthday ) time study vaccination Written inform consent HIPAA authorization obtain subject 's parent/legal representative Ability subject 's parent/legal representative understand comply requirement study Subject 's parent/legal representative available telephone Ability complete followup period 180 day study vaccination require protocol History hypersensitivity component trivalent influenza virus vaccine live , intranasal , include egg egg product , monosodium glutamate , porcine gelatin History hypersensitivity gentamicin History GuillainBarré syndrome Medically diagnose wheezing , bronchodilator use , steroid use ( systemic inhale ) , parent/legal representative report chart review , within 42 day prior study vaccination ( i.e. , child recent persistent asthma exclude ) ; history severe persistent asthma accord criterion describe National Asthma Education Prevention Program ( NAEPP ) Expert Panel Report Acute febrile ( ≥100.0°F oral equivalent ) and/or clinically significant respiratory illness ( e.g. , cough sore throat ) within 72 hour prior study vaccination Any known immunosuppressive condition immune deficiency disease ( include HIV infection ) , ongoing receipt immunosuppressive therapy Household contact immunocompromised ( subject also avoid close contact immunocompromised individual least 21 day study vaccination ) Use aspirin aspirincontaining product within 30 day prior study vaccination , expect receipt 180 day study vaccination Use antiinfluenza medication ( include amantadine , rimantadine , oseltamivir , zanamivir ) within 14 day prior study vaccination , expect receipt 28 day study vaccination Use intranasal medication within 14 day prior study vaccination , expect receipt 28 day study vaccination Administration live virus vaccine within 30 day prior study vaccination , expect receipt 30 day study vaccination Administration inactivate ( i.e. , nonlive ) vaccine within 14 day prior study vaccination , expect receipt 14 day study vaccination Receipt investigational agent within 30 day prior study vaccination , expect receipt 180 day study vaccination ( use license agent indication list package insert permit ) Receipt blood product within 90 day prior study vaccination , expect receipt 28 day study vaccination Family member household contact employee research center otherwise involved conduct study Any condition opinion investigator would interfere evaluation vaccine interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>59 Months</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>child , FluMist , shed ,</keyword>
</DOC>